<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-OV3G7133/abd08067-cf94-4566-9f26-61493c4364b0/PDF"><dcterms:extent>190 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-OV3G7133/8f788d7a-3ab2-4170-b5af-679a82ff67f8/TEXT"><dcterms:extent>31 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-OV3G7133"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2004</dcterms:issued><dc:creator>Černelč, Peter</dc:creator><dc:creator>Kokalj-Vokač, Nadja</dc:creator><dc:creator>Pajič, Tadej</dc:creator><dc:creator>Podgornik, Helena</dc:creator><dc:creator>Rupreht, Ruth</dc:creator><dc:creator>Zagorac, Andreja</dc:creator><dc:format xml:lang="sl">str. I-13 - I-17</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID_HOST:1504831</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-OV3G7133</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">Citogenetična preiskava</dc:subject><dc:subject xml:lang="sl">Cytogenetic analysis</dc:subject><dc:subject xml:lang="sl">In situ hibridizacija, fluorescenčna</dc:subject><dc:subject xml:lang="sl">In situ hybridization, fluorescence</dc:subject><dc:subject xml:lang="sl">Leukemia, myeloid</dc:subject><dc:subject xml:lang="sl">Levkemija, mieloidna</dc:subject><dc:subject xml:lang="sl">Polimerazna verižna reakcija</dc:subject><dc:subject xml:lang="sl">Polymerase chain reaction</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Citogenetične in molekularnogenetične preiskave pri ugotavljanju kronične mieloične levkemije in spremljanju zdravljenja| The role of cytogenetics and molecular genetics in diagnosis of chronic myeloid leukemia and monitoring of treatment response|</dc:title><dc:description xml:lang="sl">Background. Chronic myeloid leukemia serves as a model for the disease where the knowledge as well as the development of different new methods from molecular biology were successfully introduced into the clinical practice. Methods. Standard cytogenetic analysis were primarily used for detecting the translocation between chromosomes 9 and 22: t(9;22) while fluorescence in situ hybridization (FISH) and real time PCR (Q-RT-PCR) were mainly employed for monitoring of the disease. We evaluated the results of both molecular diagnostic methods. During the past few years the work has been done in the laboratory of the Department for haematology in Ljubljana and Laboratory for Medical Genetics in Maribor. Results. A good correlation of results obtained by both meyhods was confirmed for the period of time before the complete cytogenetic remission. We also established an initial BCR-ABL/ABL ratio of 0.94 which is a basis for later determination of a major molecular remission which is defined as &gt;/- 3 log reduction in BCR-ABL/ABL. Conclusions. Standard cytogenetic analysis of bone marrow cells is basic diagnostic approach in haematologic malignancies. At the same time FISH and PCR can also be used for confirmation of recurrent chromosomal abnormalities. FISH is the most appropriate method for CML monitoring during the first period of therapy. When cytogenetic remission is achieved, Q-RT-PCR is a method of choice. In acute leukemia PCR is mainly used in remission for the detection of malignant clone. If the clone can not be detected even by nested RT-PCR, prognosis of the disease is rather good</dc:description><dc:description xml:lang="sl">Izhodišča. Kronična mieloična levkemija (KML) je značilen primer klonske mieloproliferativne bolezni, pri kateri se citogenetična in molekularnogenetična znanja in na njih temelječe preiskave uporabljajo za natančno potrditev bolezni, za učinkovito spremljanje zmanjševanja bolezenskega klona celic med zdravljenjem, za spremljanje morebitne ponovitve bolezni in minimalnega preostanka bolezni. Metode. Za potrditev bolezni določamo translokacijo t(9;22) s standardno citogenetično preiskavo, uspešnost zdravljenja pa spremljamo z dvema molekularnogenetičnima preiskavama, fluorescenčno in situ hibridizacijo (FISH) ter verižno reakcijo s polimerazo v realnem času (Q-RT-PCR). Pregledali smo izsledke teh preiskav, ki smo jih opravili pri 40 bolnikih na Kliničnem oddelku za hematologijo v Ljubljani in Laboratoriju za medicinsko genetiko v Mariboru v zadnjih štirih letih. Rezultati. Za spremljanje KML v prvem obdobju do stabilne citogenetične remisije smo prisotnost kromosoma Philadelphia potrjevali s preiskavo FISH. Po približno letu in pol je Ph (+) celic praviloma manj kot 5-10 %, zato smo bolezen začeli spremljati s preiskavo Q-RT-PCR, nadaljevali pa smo tudi s preiskavo FISH. Ugotovili smo dobro ujemanje obeh metod pred popolno citogenetsko remisijo. Izračunali smo tudi izhodiščno vrednost razmerja prepisov BCR-ABL/ABL (0,94) in na njeni osnovi določili delež bolnikov, ki so dosegli dobro molekularno remisijo. Zaključki. Temeljna preiskava pri diagnosticiranju hematoloških novotvorb je standardna citogenetična preiskava kostnega mozga. Za ciljno potrjevanje pričakovanih kromosomskih nepravilnosti ob odkritju bolezni lahko vzporedno izvajamo tudi preiskavi FISH in PCR. Pri bolnikih z akutno levkemijo je v obdobju remisije raven rakastic celic tako majhna, da je večinoma najustreznejša preiskava PCR. Če z njo ne zaznamo prisotnosti rakastega klona, lahko zanesljivo napovemo ugoden potek bolezni</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-OV3G7133"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-OV3G7133" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-OV3G7133/abd08067-cf94-4566-9f26-61493c4364b0/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-OV3G7133/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-OV3G7133" /></ore:Aggregation></rdf:RDF>